|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
USD
0.13 billion
|
|
CAGR
(2023-2028)
|
14.83%
|
|
Fastest
Growing Segment
|
Services
Segment
|
|
Largest
Market
|
Abu
Dhabi
|
Market Overview
UAE
Next Generation Sequencing Market has valued at USD 0.13 billion in 2022 and is
anticipated to witness an impressive growth in the forecast period with a CAGR
of 14.83% through 2028. Next
Generation Sequencing (NGS), also known as high-throughput sequencing, is a
revolutionary technology that has transformed the field of genomics by enabling
rapid and cost-effective sequencing of DNA and RNA. Unlike traditional Sanger
sequencing, which is a relatively slow and labor-intensive process, NGS allows
for the simultaneous sequencing of millions to billions of DNA fragments,
making it a powerful tool for various genomic applications. The process begins
with the extraction of DNA or RNA from the biological sample of interest. The
isolated genetic material is then prepared into a sequencing library. In the
library preparation step, adaptors with unique barcodes may be added to each
DNA fragment, allowing for the identification of individual sequences in the
final data. The raw
sequencing data generated is processed through bioinformatics pipelines. This
involves base calling, which converts raw signal data into nucleotide sequences,
and subsequent steps such as alignment, variant calling, and annotation to
interpret the biological meaning of the sequences.
The
rising incidence of genetic disorders and cancer in the UAE drives the demand
for advanced genomic technologies like NGS. The technology's ability to provide
comprehensive genomic information is crucial for diagnostics, treatment
planning, and understanding the genetic basis of diseases. Continuous advancements in NGS
technologies, including improvements in sequencing accuracy, increased
throughput, and cost reduction, drive adoption. Technological innovations make
NGS more accessible and applicable to a broader range of research and clinical
applications. The
increasing focus on precision medicine, which involves tailoring medical
treatment to individual patients based on their genetic makeup, fuels the
demand for NGS. The technology enables detailed genomic profiling, allowing for
personalized therapeutic interventions. The
increasing awareness and demand for prenatal and newborn screening contribute
to the adoption of NGS technologies. NGS allows for comprehensive screening of
genetic disorders in infants, aiding in early diagnosis and intervention.
Key Market Drivers
Technological Advancements
Single-molecule sequencing
technologies, such as PacBio and Oxford Nanopore, enable the direct sequencing
of individual DNA or RNA molecules. This approach eliminates the need for
amplification and can provide longer read lengths, aiding in the assembly of
complex genomes and the detection of structural variants. Advances in
sequencing platforms have led to increased throughput, allowing researchers to
generate a higher volume of sequencing data in a shorter time. High-throughput
sequencing is crucial for large-scale genomics projects and population-scale
studies. Continuous efforts to improve sequencing chemistry and error
correction algorithms have resulted in reduced error rates. This is especially
important for applications where high accuracy is critical, such as clinical
diagnostics and genome assembly. Nanopore sequencing, offered by companies like
Oxford Nanopore Technologies, allows the direct, real-time analysis of single
DNA or RNA molecules as they pass through a nanopore. This technology has the
potential for portable sequencing devices and long-read applications. Technologies
like PacBio and Oxford Nanopore are considered third-generation sequencing
platforms. They provide long-read sequencing capabilities, which are beneficial
for resolving complex genomic regions, detecting structural variations, and
improving genome assembly.
Advances in base calling
algorithms have enhanced the accuracy of sequencing reads. This is essential
for obtaining reliable genomic information, especially in clinical applications
where precision is crucial. Ongoing efforts to reduce the cost of sequencing
have contributed to the wider accessibility of NGS technologies. Cost-effective
sequencing is vital for large-scale projects, clinical applications, and
routine use in research laboratories. NGS technologies have been adapted for
single-cell genomics, allowing researchers to study the genomic and
transcriptomic profiles of individual cells. This has implications for
understanding cellular heterogeneity and the role of rare cell populations in
diseases. Improvements in library preparation methods have streamlined
workflows and reduced the time and input DNA/RNA required for sequencing. This
contributes to the efficiency and cost-effectiveness of NGS experiments.
Integrating NGS with other
omics technologies, such as proteomics and metabolomics, allows for a more
comprehensive understanding of biological systems. Multi-omics approaches
enable researchers to explore complex biological interactions and networks. Cloud-based
solutions for NGS data analysis have emerged, enabling researchers to perform
complex bioinformatics analyses without the need for extensive computational
resources. This promotes collaboration and accessibility of data analysis
tools. Customized targeted sequencing panels allow researchers to focus on
specific regions of interest, improving the cost-effectiveness of NGS for
applications such as cancer gene panels or focused genomic studies. This factor
will help in the development of the UAE
Next Generation Sequencing Market.
Increasing Prevalence of Genetic Disorders
NGS is a powerful tool for
diagnosing genetic disorders. It enables the comprehensive analysis of an
individual's entire genome or specific genomic regions, allowing for the
identification of genetic variations associated with various disorders. NGS
allows for comprehensive genomic profiling, enabling the simultaneous analysis
of multiple genes or the entire genome. This is particularly beneficial for
identifying the genetic basis of complex and rare genetic disorders. For rare
genetic disorders, where traditional diagnostic methods may be challenging, NGS
provides a more efficient and accurate approach. It helps in identifying rare
mutations and understanding the genetic underpinnings of these conditions. NGS
is increasingly utilized in prenatal and neonatal screening programs to detect
genetic disorders early in life. The technology allows for the analysis of
fetal or newborn DNA, enabling timely interventions and management strategies.
NGS is employed for carrier
screening to identify individuals carrying genetic mutations that may be passed
on to their offspring. This is crucial for family planning and making informed
reproductive decisions. The demand for genetic counseling services has
increased with the rise in the prevalence of genetic disorders. NGS results
contribute valuable information to genetic counselors, assisting them in
providing informed guidance to individuals and families. NGS facilitates
large-scale research projects aimed at understanding the genetic basis of
various disorders. This research contributes to the discovery of new genetic
variants associated with diseases and informs the development of targeted
therapies. NGS enables the identification of disease-causing mutations,
including single nucleotide variations, insertions, deletions, and structural
variants. This information is essential for understanding the molecular basis
of genetic disorders.
The data generated by NGS
supports personalized medicine approaches, where treatment plans are tailored
to an individual's genetic profile. This is particularly relevant for genetic
disorders with targeted therapeutic options. Some regions implement
population-wide screening programs using NGS to identify individuals at risk
for specific genetic disorders. This proactive approach can lead to early
interventions and improved outcomes. Ongoing advancements in NGS technologies,
including increased speed, reduced costs, and improved accuracy, make it more
accessible for routine clinical use in diagnosing genetic disorders. This
factor will pace up the demand of the UAE
Next Generation Sequencing Market.
Rising Demand for Prenatal and Newborn Screening
NGS
enables early detection of genetic disorders in fetuses and newborns. The technology
allows for a comprehensive analysis of the entire genome, providing insights
into potential genetic abnormalities and disorders. NGS allows for
comprehensive screening of a wide range of genetic variants simultaneously.
This is crucial for identifying various genetic conditions, including both
common and rare disorders. NGS is widely used in non-invasive prenatal testing,
where fetal DNA obtained from maternal blood is analyzed. This approach
provides a safer alternative to traditional invasive procedures, such as
amniocentesis, for detecting chromosomal abnormalities.
For
rare genetic disorders, NGS provides a powerful tool for identifying specific
mutations that may not be covered by traditional screening methods. This is
particularly important for conditions with a low prevalence but significant
clinical impact. NGS is used for carrier screening in parents, helping to
identify carriers of genetic mutations that may pose a risk to their offspring.
This information is valuable for family planning and making informed
reproductive decisions. NGS contributes to personalized medicine approaches in
neonatal care. By identifying genetic factors early on, healthcare providers
can tailor treatment plans to address the specific needs of newborns with
genetic disorders. Early identification of genetic disorders through NGS allows
for timely interventions and treatment planning. This can include medical
interventions, counseling for parents, and preparation for potential medical
challenges the newborn may face.
NGS
is employed to screen for inherited conditions that may have a familial
component. This information is crucial for understanding the genetic risk
within families and providing appropriate medical care and guidance. NGS
supports research initiatives focused on understanding the genetics of neonatal
conditions. These studies contribute to the identification of new genetic
variants and potential therapeutic targets. NGS allows for the expansion of
newborn screening panels, enabling simultaneous testing for a broader range of
genetic disorders. This helps ensure that more conditions are considered in the
early screening process. This factor will accelerate the demand of the UAE
Next Generation Sequencing Market.
Download Sample Report
Key Market Challenges
Costs
and Affordability
The acquisition of NGS instruments and
platforms involves a significant upfront capital investment. High initial costs
can be a barrier, particularly for smaller research institutions, clinical
laboratories, and startups. Beyond the initial investment, ongoing operational
costs include the purchase of consumables such as reagents, sequencing kits,
and other supplies. These costs can contribute significantly to the overall
expense of running NGS experiments. The storage and analysis of large volumes
of NGS data can be resource intensive. Costs associated with data storage,
computational infrastructure, and bioinformatics analysis tools contribute to
the overall cost of implementing NGS technologies. Staying current with the
latest advancements in NGS technologies often requires updates to instruments
and software. Additionally, routine maintenance and calibration of NGS
equipment contribute to ongoing operational costs. Building and maintaining a
skilled workforce with expertise in NGS technologies is essential. Training
personnel to operate NGS instruments and analyze data requires investment in
education and professional development. Large-scale sequencing projects may
benefit from economies of scale, leading to lower per-sample costs. However,
for smaller-scale projects or individual sample analyses, the cost per sample
can be relatively higher.
Variability in Quality and
Standards
Variances
in the accreditation and certification of NGS laboratories can result in
differences in the quality of services provided. Standardized accreditation
processes ensure that laboratories adhere to established quality and
performance standards, promoting consistency in results. Differences in the
implementation of quality control protocols among laboratories can lead to
variations in the accuracy and reliability of NGS data. Standardized quality
control measures are essential for ensuring the reproducibility of results
across different laboratories. Variability in the bioinformatics pipelines used
for NGS data analysis can impact the consistency and accuracy of results.
Standardized and validated analysis workflows are crucial for minimizing
discrepancies in variant calling and data interpretation. The use of different
reference materials and standards by laboratories can introduce variability in
the calibration and normalization of NGS instruments. Standardized reference
materials help ensure accuracy and comparability across different platforms. Variability
in sample handling, extraction methods, and library preparation techniques can
introduce biases and affect the quality of NGS data. Standardized protocols for
sample processing and preparation are essential for minimizing variations. The
interpretation of genetic variants identified through NGS can vary among
different laboratories or clinicians. Consistent guidelines for variant
interpretation, particularly in the context of clinical applications, are
crucial for accurate diagnosis and treatment decisions.
Key Market Trends
Integration of NGS in Clinical
Practice
NGS
plays a crucial role in advancing precision medicine approaches, tailoring
medical treatments based on the individual's genomic profile. Clinicians can
use genomic information to select targeted therapies and optimize treatment
plans for better patient outcomes. NGS is utilized for diagnosing genetic
disorders, identifying disease-causing mutations, and assessing the risk of
hereditary conditions. In clinical genetics, NGS enables comprehensive testing
for a wide range of genetic abnormalities. NGS has become integral to cancer
genomics, allowing for the identification of somatic mutations, assessment of
tumor heterogeneity, and the development of personalized cancer treatment
strategies. Molecular profiling using NGS guides targeted therapy selection in
oncology. In clinical obstetrics and pediatrics, NGS is employed for prenatal
and neonatal screening. It enables the early detection of genetic disorders in
fetuses and newborns, informing timely interventions and treatment plans. NGS
is used to analyze the genetic variations that influence drug metabolism and
response. This information guides clinicians in prescribing medications that
are most likely to be effective and well-tolerated by individual patients. NGS
is applied in clinical microbiology for the genomic analysis of infectious
agents. It helps in understanding the genetic diversity of pathogens, tracking
outbreaks, and guiding the selection of appropriate antimicrobial treatments. NGS
facilitates the diagnosis of rare genetic diseases, where traditional
diagnostic methods may be challenging. Whole exome sequencing and whole genome
sequencing are particularly valuable for identifying rare mutations.
Segmental Insights
Technology Insights
In 2022, the UAE Next Generation Sequencing Market largest share
was held by lon Semiconductor Sequencing segment and is predicted to continue
expanding over the coming years. Ion Semiconductor Sequencing, often
associated with Ion Torrent sequencing technology, has experienced continuous
advancements. These improvements may include enhanced accuracy, increased
throughput, and reduced costs, making the technology more attractive to users
in the UAE NGS market. Ion Semiconductor Sequencing is known for its rapid
sequencing process, allowing for quick turnaround times in obtaining genomic
data. The speed and efficiency of this technology may be a key factor in its
adoption, especially in applications where timely results are crucial. Ion
Semiconductor Sequencing is well-suited for targeted sequencing applications.
This is particularly valuable in genomics research and diagnostics, where
specific regions of interest in the genome need to be sequenced with high
accuracy. Ion Semiconductor Sequencing has demonstrated reliability and
accuracy in clinical applications, it may gain prominence in the UAE market.
Clinical settings often prioritize technologies that can deliver precise
results for diagnostic and treatment decision-making. The Ion Semiconductor
Sequencing platform has been positioned as a cost-effective option compared to
some other NGS technologies. Affordability and accessibility can be significant
drivers for its adoption, particularly in research institutions and clinical
laboratories.
Application Insights
In 2022, the UAE Next Generation Sequencing Market largest share
was held by Biomarkers & Cancer segment and is predicted to continue
expanding over the coming years. NGS plays a pivotal role in precision
oncology by enabling the comprehensive analysis of cancer genomes. This
technology helps identify specific genetic mutations and alterations associated
with diverse types of cancer. The ability to profile the genomic landscape of
tumors allows for personalized treatment approaches. NGS facilitates the
discovery of molecular biomarkers that can serve as indicators of cancer
presence, progression, or response to treatment. These biomarkers are crucial
for developing diagnostic tests and guiding therapeutic decisions in cancer
care. The Biomarkers & Cancer segment often involves the use of NGS for
comprehensive genomic profiling of tumors. This approach provides a holistic
view of the genetic alterations within cancer cells, aiding in the
identification of potential therapeutic targets and guiding treatment
strategies. NGS is increasingly used in liquid biopsies, where circulating
tumor DNA (ctDNA) or other biomolecules in bodily fluids are analyzed. This non-invasive
approach allows for real-time monitoring of cancer and the detection of minimal
residual disease, improving early detection and treatment monitoring. The
identification of specific genetic mutations through NGS enables the
development and prescription of targeted therapies. Pharmaceutical companies
and healthcare providers in the Biomarkers & Cancer segment leverage NGS
data to match patients with the most effective and personalized treatment
options.
End-User Insights
In 2022, the UAE Next Generation Sequencing Market largest share
was held by Pharmaceutical
& Biotechnology Companies segment in the forecast period and is predicted to continue
expanding over the coming years. Pharmaceutical companies extensively use
NGS technologies in drug discovery and development processes. NGS allows for
high-throughput sequencing of genomes, enabling the identification of genetic
variations associated with diseases. This information is crucial for developing
targeted and personalized therapies. Precision medicine, which involves
tailoring medical treatments to the individual characteristics of patients,
relies heavily on genomic information. Pharmaceutical companies leverage NGS to
identify biomarkers and genetic variations that can guide the development of
precision medicine approaches. Pharmaceutical and biotechnology companies often
invest significantly in research and development. The adoption of NGS
technologies enhances their capabilities in genomics research, enabling a
deeper understanding of diseases, identification of therapeutic targets, and
development of novel therapies. NGS is utilized in clinical trials for patient
stratification, biomarker discovery, and monitoring treatment responses.
Pharmaceutical companies leverage NGS data to identify and validate biomarkers
that can aid in patient selection and assessment of treatment efficacy. Collaboration
between pharmaceutical companies and research institutions can drive
advancements in genomics research. By working with academic and research
partners, pharmaceutical companies can access cutting-edge NGS technologies and
expertise. NGS plays a crucial role in the development of diagnostic tests and
companion diagnostics. Pharmaceutical companies involved in developing targeted
therapies often use NGS to identify specific genetic markers that can guide
treatment decisions.
Download Sample Report
Regional Insights
The Abu Dhabi region dominates
the UAE Next Generation Sequencing Market in 2022. Regions with
well-established research and healthcare infrastructure are often at the
forefront of adopting advanced technologies such as Next Generation Sequencing.
If Abu Dhabi invested significantly in these areas, it could contribute to its
dominance. Government support and funding for genomics research and healthcare
initiatives play a crucial role. If Abu Dhabi has implemented specific policies
or provided substantial funding for NGS projects, it could lead to the
dominance of the region in the market. The presence of leading research
institutions, universities, and healthcare facilities with a focus on genomics
can attract NGS-related activities. If Abu Dhabi hosts such institutions, it
could contribute to its dominance in the NGS market. Collaborations between
academic institutions, healthcare providers, and industry partners can create a
conducive environment for the growth of the NGS market. If Abu Dhabi has
established effective collaborations, it may contribute to its dominance. The Abu Dhabi region has prioritized genomic
medicine and the integration of NGS into clinical practices, it could lead to
increased demand and utilization of NGS technologies.
Recent Developments
- In March 2023, The UAE has
initiated its National Genome Strategy, designed to establish a thorough
legislative and governance framework facilitating the creation and execution of
genomic programs. Spanning a decade, the strategy aims to address public health
priorities and enhance the nation's overall well-being. Oversight for the
National Genome Strategy is vested in the Emirates Genome Council, formed in
2021, which has made substantial strides in establishing the foundation for
regulatory, research, technological, and medical institutions to foster
connectivity, collaboration, and the development of advanced medical
applications and services.
- In June 2021, In the United
Arab Emirates (UAE), a groundbreaking institution, the Centre for Genomic
Discovery, has been introduced with the unique objective of advancing local
genomic research and providing diagnoses and treatments for individuals with
genetic disorders. This collaborative endeavour is established through a
partnership between the Mohammed Bin Rashid University of Medicine and Health
Sciences (MBRU) and the Al Jalila Genomics Centre of the Al Jalila Children’s
Specialty Hospital (AJCH).
Key Market Players
- Oxford Nanopore UAE
- Agiomix Labs
- Illumina UAE
- Thermo Fischer Scientific UAE
- PerkinElmer UAE
- Alliance Global UAE
|
By
Product
|
By Application
|
By
End-User
|
By
Technology
|
By
Region
|
- Consumables
- Platforms
- Services
|
- Biomarkers
& Cancer
- Diagnostics
- Reproductive
Health
- Personalized
Medicine
- Agriculture
& Animal Research
- Others
|
- Academic
& Clinical Research Centers
- Pharmaceutical
& Biotechnology Companies
- Hospitals
& Clinics
- Others
|
- Sequencing
by Synthesis
- lon
Semiconductor Sequencing
- Sequencing
by Ligation
- Single
Molecule Real Time Sequencing
- Others
|
- Dubai
- Abu
Dhabi
- Sharjah
- Rest
of UAE
|
Report Scope:
In this report, the
UAE Next Generation Sequencing Market has
been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Next Generation Sequencing Market, By Product:
o Consumables
o Platforms
o Services
- Next Generation
Sequencing Market, By Technology:
o Sequencing by Synthesis
o lon Semiconductor Sequencing
o Sequencing by Ligation
o Single Molecule Real Time Sequencing
o Others
·
Next Generation
Sequencing Market, By Application:
o Biomarkers & Cancer
o Diagnostics
o Reproductive Health
o Personalized Medicine
o Agriculture & Animal Research
o Others
- Next
Generation Sequencing Market, By End-User:
o Academic & Clinical Research Centers
o Pharmaceutical & Biotechnology
Companies
o Hospitals & Clinics
o Others
- Next Generation Sequencing
Market, By region:
o
Dubai
o
Abu
Dhabi
o
Sharjah
o
Rest
of UAE
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies presents in the UAE Next
Generation Sequencing Market.
Available Customizations:
UAE Next
Generation Sequencing Market report with
the given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
UAE Next Generation Sequencing Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]